{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:19:42Z","timestamp":1740165582483,"version":"3.37.3"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PLx Pharma"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015828","name":"Osprey Medical, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015828","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","interventional.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.iccl.2016.08.006","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T07:01:58Z","timestamp":1479884518000},"page":"67-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Switching P2Y12 Receptor Inhibiting Therapies"],"prefix":"10.1016","volume":"6","author":[{"given":"Fabiana","family":"Rollini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iccl.2016.08.006_bib1","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.006_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.006_bib3","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.006_bib4","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu283","volume":"35","author":"Authors\/Task Force Members","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.006_bib5","doi-asserted-by":"crossref","first-page":"e000849","DOI":"10.1161\/JAHA.114.000849","article-title":"Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry","volume":"3","author":"Sherwood","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.iccl.2016.08.006_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2048872614565912","article-title":"Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns","volume":"5","author":"Bueno","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.iccl.2016.08.006_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.006_bib8","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.006_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","article-title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease","volume":"13","author":"Rollini","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: a review on pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.iccl.2016.08.006_bib12","unstructured":"Cangrelor United States full prescribing information. Available at: http:\/\/www.kengreal.com\/pdfs\/kengreal-us-prescribing-information.pdf. Accessed July 30, 2016."},{"key":"10.1016\/j.iccl.2016.08.006_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.iccl.2016.08.006_bib14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2165\/11640880-000000000-00000","article-title":"The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day","volume":"72","author":"Angiolillo","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.iccl.2016.08.006_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.iccl.2016.08.006_bib16","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jacc.2012.02.042","article-title":"Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.iccl.2016.08.006_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.006_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.006_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/09537100801891640","article-title":"Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects","volume":"19","author":"Payne","year":"2008","journal-title":"Platelets"},{"key":"10.1016\/j.iccl.2016.08.006_bib21","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.006_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","article-title":"Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study","volume":"103","author":"Montalescot","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.006_bib23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","article-title":"Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study","volume":"56","author":"Angiolillo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib24","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/CIRCINTERVENTIONS.112.000063","volume":"6","author":"Diodati","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv744","article-title":"A\u00a0head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study","author":"Rollini","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.006_bib27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCINTERVENTIONS.112.972463","article-title":"Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial","volume":"5","author":"Sardella","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijcard.2014.04.208","article-title":"Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity","volume":"174","author":"Lhermusier","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1471-2261-14-189","article-title":"A\u00a0pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI","volume":"14","author":"Koul","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.iccl.2016.08.006_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijcard.2012.09.214","article-title":"Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy","volume":"168","author":"Cuisset","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/09537104.2012.736045","article-title":"Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study","volume":"24","author":"N\u00fchrenberg","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.iccl.2016.08.006_bib33","first-page":"395","article-title":"Switching from clopidogrel to prasugrel in patients having coronary stent implantation","volume":"38","author":"Parodi","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.iccl.2016.08.006_bib34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jacc.2013.12.023","article-title":"Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel","volume":"63","author":"Aradi","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1160\/TH13-10-0874","article-title":"A\u00a0comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry","volume":"112","author":"Mayer","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.006_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joic.12139","article-title":"Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity","volume":"27","author":"Lhermusier","year":"2014","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib37","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.006_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCINTERVENTIONS.113.000512","article-title":"Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome","volume":"7","author":"Caiazzo","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib39","doi-asserted-by":"crossref","first-page":"e92078","DOI":"10.1371\/journal.pone.0092078","article-title":"A\u00a0comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study","volume":"9","author":"Hibbert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.iccl.2016.08.006_bib40","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.006_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1160\/TH12-06-0378","article-title":"Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study","volume":"109","author":"Saucedo","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.006_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2010.11.025","article-title":"The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET\/OFFSET and RESPOND studies","volume":"162","author":"Bliden","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2016.08.006_bib43","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib44","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/2048872614564082","article-title":"In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study","volume":"4","author":"Bagai","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.iccl.2016.08.006_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2013.10.010","article-title":"In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome","volume":"167","author":"Alexopoulos","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2016.08.006_bib47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/2048872614560505","article-title":"Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study","volume":"4","author":"De Luca","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.iccl.2016.08.006_bib48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2048872614547449","article-title":"MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel - the European MULTIPRAC Registry","volume":"4","author":"Clemmensen","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.iccl.2016.08.006_bib49","doi-asserted-by":"crossref","first-page":"e000384","DOI":"10.1136\/openhrt-2015-000384","article-title":"Switching between thienopyridines in patients with acute myocardial infarction and quality of care","volume":"3","author":"Schiele","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.iccl.2016.08.006_bib50","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.114.001555","article-title":"In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry","volume":"7","author":"Bagai","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11239-013-1039-0","article-title":"Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience","volume":"38","author":"De Luca","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.iccl.2016.08.006_bib52","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjcard.2012.11.058","article-title":"Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"111","author":"Loh","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11239-014-1139-5","article-title":"Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'","volume":"39","author":"Almendro-Delia","year":"2015","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.iccl.2016.08.006_bib54","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.006_bib55","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.006_bib56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","article-title":"Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events a secondary analysis of the PEGASUS-TIMI 54 trial","volume":"1","author":"Bonaca","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"10 Suppl","key":"10.1016\/j.iccl.2016.08.006_bib57","article-title":"Optimizing crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome: the CAPITAL OPTI-CROSS randomized trial","volume":"65","author":"Pourdjabbar","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcin.2012.09.012","article-title":"Switching acute coronary syndrome patients from prasugrel to clopidogrel","volume":"6","author":"Kerneis","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib59","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1016\/j.ijcard.2013.07.121","article-title":"Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study","volume":"168","author":"Deharo","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib60","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jacc.2013.11.032","article-title":"Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (switching anti platelet-2)","volume":"63","author":"Angiolillo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib61","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcin.2016.02.039","article-title":"Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study","volume":"9","author":"Franchi","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","article-title":"Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect","volume":"121","author":"Steinhubl","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.iccl.2016.08.006_bib63","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1538-7836.2008.03020.x","article-title":"The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function","volume":"6","author":"Dovlatova","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.006_bib64","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2013.11.019","article-title":"Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients","volume":"7","author":"Rollini","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","article-title":"Pharmacodynamic effects during the transition between cangrelor and ticagrelor","volume":"7","author":"Schneider","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.006_bib66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","article-title":"Pharmacodynamic effects during the transition between cangrelor and prasugrel","volume":"26","author":"Schneider","year":"2015","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.iccl.2016.08.006_bib67","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/joic.12229","article-title":"Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation","volume":"28","author":"Schneider","year":"2015","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.iccl.2016.08.006_bib68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14740338.2016.1133585","article-title":"A\u00a0safety evaluation of cangrelor in patients undergoing PCI","volume":"15","author":"Franchi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.iccl.2016.08.006_bib69","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.006_bib70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.iccl.2016.08.006_bib71","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221174581630089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221174581630089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:07:53Z","timestamp":1657814873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221174581630089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S221174581630089X"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.006","relation":{},"ISSN":["2211-7458"],"issn-type":[{"type":"print","value":"2211-7458"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching P2Y12 Receptor Inhibiting Therapies","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}